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Background: External beam radiotherapy (EBRT) is the treatment of choice for irresectable meningioma. Due to the
strong expression of somatostatin receptors, peptide receptor radionuclide therapy (PRRT) has been used in
advanced cases. We assessed the feasibility and tolerability of a combination of both treatment modalities in
advanced symptomatic meningioma.
Methods: 10 patients with irresectable meningioma were treated with PRRT (177Lu-DOTA0,Tyr3 octreotate or -
DOTA0,Tyr3 octreotide) followed by external beam radiotherapy (EBRT). EBRT performed after PRRT was continued
over 5–6 weeks in IMRT technique (median dose: 53.0 Gy). All patients were assessed morphologically and by
positron emission tomography (PET) before therapy and were restaged after 3–6 months. Side effects were
evaluated according to CTCAE 4.0.
Results: Median tumor dose achieved by PRRT was 7.2 Gy. During PRRT and EBRT, no side effects>CTCAE grade 2
were noted. All patients reported stabilization or improvement of tumor-associated symptoms, no morphologic
tumor progression was observed in MR-imaging (median follow-up: 13.4 months). The median pre-therapeutic
SUVmax in the meningiomas was 14.2 (range: 4.3–68.7). All patients with a second PET after combined PRRT + EBRT
showed an increase in SUVmax (median: 37%; range: 15%–46%) to a median value of 23.7 (range: 8.0–119.0; 7
patients) while PET-estimated volume generally decreased to 81 ± 21% of the initial volume.
Conclusions: The combination of PRRT and EBRT is feasible and well tolerated. This approach represents an attractive
strategy for the treatment of recurring or progressive symptomatic meningioma, which should be further evaluated.
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While surgery is the mainstay in treatment of meningi-
oma, external beam radiotherapy (EBRT) offers the only
other curative option in meningioma management [1, 2].
For benign (WHO Grade 1) tumors, recommended
doses are generally 50–54 Gy in fractions of 1.8–2 Gy,
alternatively single doses of 12–16 Gy are used in* Correspondence: rajsweeney@yahoo.com
2Department of Radiation Oncology, University Hospital Wuerzburg
University of Wuerzburg, Josef-Schneider-Str. 11 97080, Wuerzburg, Germany
Full list of author information is available at the end of the article
© 2012 Kreissl et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orradiosurgery [1-3]. No clear dose–response relationship
has been established justifying higher doses to date.
However, especially higher grade meningiomas
(≥WHO II), large, irregular tumors in critical locations
and recurrent tumors in both radiation-naive as well as
previously irradiated regions would likely benefit from a
highly conformal dose escalation without increasing dose
to normal tissues [4, 5]
In case of a recurrence after external radiotherapy,
results of studies using pharmacological targeted
approaches have been modest at best and are often asso-
ciated with significant toxicities [6].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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apy in advanced meningioma is the somatostatin recep-
tor (SSR). About 90% of the meningiomas show SSR
expression, especially the receptor subtypes 1 and 2 [7].
Positron emission tomography using 68Ga-labelled som-
atostatin analogues (SSR-PET) and single photon emis-
sion computed tomography (SPECT) using 111In-
octreotid are well established for imaging neuroendo-
crine tumors and have also shown very promising results
for the diagnostic work up and for target volume delin-
eation in radiotherapy treatment planning of meningi-
oma [8-10]. Since many tumors display a fairly strong
expression of somatostatin receptors, “peptide receptor
radionuclide therapy” (PRRT), which is well evaluated
and commonly used in neuroendocrine tumors [11, 12],
has already been used in advanced cases of meningioma
showing promising results [13-15]. However, in the lar-
gest study, published by Bartolomei et al., about one
third of the patients showed tumor progression after
therapy [15].
In order to increase efficacy of treatment, it seems rea-
sonable to combine external beam radiotherapy and
PRRT therapy. Besides delivering a higher radiation dose
to the tumor, this approach could also be used to reduce
the external beam radiation dose to critical organs at
risk next to the tumor such as cranial nerves, brainstem
and normal brain. Due to the short range of beta parti-
cles, somatostatin analogues labelled with [177Lu], suchTable 1 Patient baseline characteristics
Pat.
no.
Age
(y)
Sex WHO
grade
Karnofsky
score
Meningioma location Prior
Resection
Prio
RT
1 27 f II 90 Right sphenoid wing 2 -
2 55 f I 100 Both sphenoid wings 1 0
3 68 f NA* 90 Left petroclival 0 0
4 53 f I 80 Right sphenoid wing 2 0
5 52 f I 100 Both sphenoid wings 1 0
6 65 f I 100 Right sphenoid wing 1 0
7 62 f I 80 Left falx & vertexregion 1 0
8 63 m II 90 Falx central region 1 1
9 69 f I 90 Left olfactory nerve &
neurinoma of ethmoidal
sinus}
1 0
10 67 m I 90 Multifocal bifrontal to
right sphenoid wing
2 0
* Biopsy not possible.
} SSR-expression only in the meningioma, radiotherapy of both, meningioma and n
# Ga-DOTATOC.
+ Ga-DOTATATE.
CN =Cranial Nerve.as 177Lu- DOTATATE (177Lu DOTA0,Tyr3 octreotate)
and [177Lu]-DOTATOC (177Lu-DOTA0,Tyr3octreotide)
are of special interest.
We herein report the tolerance and feasibility of a
combined PRRT-EBRT approach with one cycle of radio-
peptide therapy preceeding EBRT in patients with symp-
tomatic non-resectable meningioma.Materials and methods
Patients
From May 2010 to May 2011, 10 patients with irresectable
advanced primary or recurrent meningioma (7 WHO
grade I, 2 grade II, 1 not known) were treated with radio-
peptide therapy and EBRT. As part of treatment planning,
all patients received somatostatin receptor PET to assess
not only SSR expression but also for a more accurate de-
lineation of the target volume. All cases were initially dis-
cussed and assigned to the pilot trial in unanimous
decision in an interdisciplinary tumor board including
physicians from neurosurgery, radiation oncology, neuror-
adiology, nuclear medicine and medical oncology. The
combined treatment was performed according to German
law on a compassionate use basis. All patients gave their
informed consent for the procedure. Patient characteris-
tics can be found in Table 1. All except one patient had
one or more previous surgeries; one had been previously
treated with radiotherapy.r Mag3 Clearance
(% of norm)
PTV (ml) Indication for intensified protocol /
clinical presentation
67.7 115 Large tumor, grade II, age/ pituitary
insufficiency, decreased vision /ptosis
82.4 223 Very large tumor / retroorbital pressure,
73.9 73 Critical location / Paresis of CN III, VI & VII
87.1 38 Critical location / exophthalmus and
chemosis right eye, progressive
loss of vision
61.7 197 Large tumor critical location /, progressive
loss of vision
83.2 29.3 Critical location /trigeminal hypesthesia
89.4 139 Clear-cell component, quickly
progressive hemiparesis
112.7 28 Previous RT, Grade II, large tumor /
paresis left leg
82.9 121 Large tumor/ epilepsy, tremor
108.3 294 Ver large tumor/ dizziness, swelling
and ptosis right palpebra
eurinoma.
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All patients were assessed for somatostatin receptor ex-
pression by PET prior to initiation of PRRT. Until Septem-
ber 2010 [68Ga-DOTA0,Tyr3]octreotide (Ga-DOTATOC)
was employed; due to a change in availability of the pre-
cursor peptide, [68Ga-DOTA0,Tyr3]octreotate (Ga-
DOTATATE) was used thereafter. The somatostatin
analogue for PRRT was switched simultaneously for the
same reason.
Also, until September 2010, a dedicated PET (Siemens
ECAT Exact 47) was used for SSR-PET in the first 6
patients; afterwards a newly installed PET/CT (Siemens
Biograph mCT 64) was used.
Data sets of the head were acquired 60 minutes after
the injection of 111 ± 35 MBq 68Ga-DOTATOC/DOTA-
TATE. For the dedicated PET, 3D data were collected
for 20 min and corrected for attenuation using Ge-68
line sources, data were reconstructed using filtered back
projection.
On the PET/CT, a 10 min 3D data acquisition (matrix:
200 x 200) was started after a low-dose-CT (30 mAs,
120 kV, slice thickness 0.5 mm). After decay and scatter
correction, PET data were reconstructed iteratively with
attenuation correction using dedicated software (HD.
PET, Siemens Esoft).
The maximum standardized uptake value SUVmax as
well as the mean SUV in a spherical volume of inter-
est 1 cm in diameter (SUVpeak) in the tumor region
with highest tracer uptake were determined (Table 2).
PET data were utilized to estimate the tumor volumes
(Table 2). The tumors were delineated with the software
ROVER (ABX Germany [16]) by setting thresholds rela-
tive to the maximum SUV in the PET data sets, which
provided acceptable recovery of the volumes of spheres
with comparable sizes in phantom measurements (un-
published Data by MCK and HH).Table 2 Details on PET diagnostics
PET before therapy
Patient no. Scanner 68 Ga- peptide SUVmax SUVpeak Volume
1 ECAT DOTATOC 11.4 10.0 28.9
2 ECAT DOTATOC 44.8 38.8 11.8
3 ECAT DOTATOC 13.1 11.4 9.6
4 ECAT DOTATOC 4.3 3.5 7.7
5 mCT DOTATOC 34.2 29.8 32.6
6 ECAT DOTATOC 68.7 59.7 4.1
7 mCT DOTATATE 14.6 13.1 7.1
8 mCT DOTATATE 9.2 7.1 3.6
9 mCT DOTATATE 35.8 27 6.3
10 mCT DOTATATE 13.7 10.1 13.9
ECAT = Siemens ECAT Exact 47+; mCT = Siemens Biograph mCT 64; SUVmax =maxim
1 cm diameter; Volume= tumor volume measured from PET data.Prior to PRRT, a preexisting reduced renal function
was excluded using 99mTc-MAG3; calculated clearance
values were always >50 percent of the normal values,
adjusted for age and body surface. Pregnancy was
excluded by β-HCG test.
The PRRT followed a standardized protocol with in-
fusion of 1500 mL of lysine-arginine solution (2.5% of
lysine and 2.5% of arginine) starting 30 minutes at of
500 mL/hour before therapy for renal protection and
standardized antiemetic medication (Ondansetron
4 mg p.o.). Radionuclide therapy was administered
over 15–20 minutes using a shielded infusion pump
system. Patients remained in the radionuclide therapy
ward for 4–5 days.
For dosimetry, whole body scans with a [177Lu]
standard were performed daily during hospitalization
starting on the day of radionuclide administration
(Siemens Ecam Duet, medium energy collimator, 20%
window around the 208 keV peak, matrix 256 × 1024,
scan speed 20 cm/min) and decay kinetics in the total
body and the whole tumor were determined. Add-
itionally, a SPECT/CT of the head was acquired 4–
5 days after treatment (Siemens Symbia T2, equipped
with a medium energy collimator). SPECT/CT data
were reconstructed iteratively (3D-OSEM, 6 subsets, 6
iterations, Gauss filter of 8 mm); both attenuation
and scatter were corrected for. The sensitivity of the
SPECT/CT scanner in counts/second/kBq was deter-
mined from calibration with 177Lu activity standards
in a head phantom. For technical reasons, SPECT/CT
could not be performed in one patient. Assuming
equal decay kinetics in all voxels of the tumor, the
tumor decay function was normalized to the absolute
activity value measured by SPECT/CT for the voxel
with the highest uptake to deduce the maximum
voxel dose Dvox.Follow-up PET
cm³ Scanner 68 Ga- peptide SUVmax SUVpeak Volume cm³
ECAT DOTATOC 18.0 14.9 25.2
ECAT DOTATATE 54.1 47.9 12.6
mCT DOTATATE 20.3 15.3 7.9
mCT DOTATATE 8.0 5.3 3.5
mCT DOTATATE 40.4 32.1 34.2
mCT DOTATATE 119.0 87.3 3
mCT DOTATATE 23.7 14.5 4.9
um standardised uptake value; SUVpeak = highest SUV in a spherical region with
Figure 1 Intensity modulated radiotherapy isodose map of patient no. 2. This patient has a large meningioma with bitemporal spread
surrounding the optic nerves and chiasm. Shown are transversal (upper left), sagittal (lower left) and coronal (right) views. In order to err on the
side of caution due to the estimated 6.6 Gy PRRT dose, the optic tract was limited to 45 Gy (thick green line) and the PTV encompassing dose
was limited to 49 Gy (thick orange line) instead of the originally planned 54 Gy
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EBRT was initiated no later than 9 days (median 2 days)
after discharge of the patient from the radionuclide ther-
apy ward.
SSR-PET and contrast enhanced volumetric MR-
images were coregistered with the planning CT for all
patients and respective GTV (gross tumor volume),
CTV (clinical target volume) and PTV (planning target
volume) delineated. Intensity-modulated radiation ther-
apy plans were implemented in all cases. 1.8–2.0 Gywere delivered to the D95 surrounding the PTV to a
total dose of 40–60 Gy. The total dose depended not
only upon treatment volume, location and previous RT,
but also on the calculated best estimate of dose from the
PRRT at the discretion of the responsible radiation on-
cologist (RAS, MF). Thus, if vision was to be preserved,
the maximum dose for the optic organs at risk was
54 Gy (D01) but, depending on previous RT or calcu-
lated PRRT-dose, also substantially lower (i.e.only 45 Gy
in patient 2 as shown in Figure 1). All patients were
Table 3 Summary of the patients’ therapies and follow-up results
Pat.
no.
177Lu-
DOTATOC/
DOTATATE
Therapeutic
activity
(GBq)
Whole
body
residence
time (h)
Maximum
voxel activity
(kBq)#
Lifetime
in Tumor
(h)}
Maximum
absorbed
voxel dose
(Gy)
Gy/GBq EBRT
target
dose
(Gy)
No. of
fractions
used for
EBRT
dose
delivery
Change
of EBRT
dose due
to PRRT
(Gy)
Follow-up
MR
Follow–up symptoms
1 DOTATOC 7.0 39.3 71 72.4 4.0 0.57 60 30 0 No change Improvement of pituitary
insufficiency,decreased
vision unchanged
2 DOTATOC 7.3 19.1 277 29.7 6.6 0.90 48.6 27 −7 No change Retroorbital pressure
fully resolved
3 DOTATOC 7.5 25.7 NA 60.1 4.0* 0.53 50 28 −4 No change Cranial nerve palsy
fully resolved
4 DOTATOC 7.2 14.7 3 94.2 0.2 0.03 54 30 0 Complete
remission
Exophthalmus fully
resolved
5 DOTATOC 7.6 17.1 191 44.0 6.7 0.88 54 30 0 No change Partial loss of vision,
decresed general
performance constant
6 DOTATOC 7.9 22.1 539 52.4 22.3 2.82 42 22 −11 No change Headache, hypesthesia
improved
7 DOTATATE 7.9 27.2 557 68.2 30.7 3.89 60 30 0 No change Hemiparesis unchanged
8 DOTATATE 7.2 26.6 124 74.6 7.2 1.00 40 20 0 No change Paresis left leg unchanged
9 DOTATATE 7.3 32.3 305 69.6 16.6 2.27 54 30 0 Partial
remission
Epilepsy, tremor worsened,
new hearing problems,
resolved to pretherapeutic
state after 2 months
10 DOTATATE 7.4 32.5 161 64.8 8.2 1.11 52 20 −6 No change Dizziness, ptosis constant
# at 1 hour p.a. in 0.11 cm³ voxel volume.
} tumor residence time normalized to initial uptake.
* no SPECT/CT data available, value deduced from PET uptake.
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Figure 2 Post-therapeutic whole body scans (anterior and
posterior views) obtained 23 hours after PRRT of patient 2.
Strong persistent uptake of the radiotherapeutic agent can be
observed in the meningioma (thick arrow), which also extends to
the contralateral side (thin arrow)
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guided with at least weekly conebeam CT [17].
Evaluation of toxicity and tumor response
Evaluation preceding therapy included standard docu-
mentation of the patient’s history and physical examin-
ation. Serum chemistry and a complete blood cell count
were obtained. Drug- and radiotherapy-related adverse
events and toxicities were evaluated according to the
Common Toxicity Criteria of the National Cancer Insti-
tute (version 4.0). At four weeks and 3–6 months after
therapy, symptoms also were reassessed in the out-
patient clinic of the department of radiation oncology; at
these occasions serum chemistry and a complete blood
cell count were obtained again. For tumor evaluation,
contrast enhanced MR imaging was performed for all
patients; <25% volume change was considered stable
disease, >25% volume increase progressive disease and>25% decrease was deemed partial remission. SSR-PET
was performed additionally after 3 – 6 months in 7
patients.
Statistical methods
Statistical Package for Social Sciences (SPSS version
19.0; SPSS Inc.) was used for statistical analyses. Con-
tinuous variables with a normal distribution were
recorded as mean ± standard deviation (SD), for those
without normal distribution, the median and the range
are mentioned. For the assessment of the correlation
uptakes in PET and doses due to PRRT, a Spearman rank
test was used. A P-value of 0.05 or smaller was consid-
ered to indicate significance.
Results
PRRT
7.4±0.3 GBq of 177Lu-DOTATOC/-DOTATATE were
administered (Table 3). While mean total body residence
time was 25.7 ± 7.7 h (range: 14.7–39.3 h), maximum ac-
tivities in the tumor per 0.11 cm³ voxel at 1 hour p.a.
back-extrapolated from SPECT/CT ranged from 3 to
557 kBq corresponding to 0.4*10-6 to 70.5*10-6 of the
administered activity. The mean lifetime of the activity
in the voxels was 63.0 ± 17.7 h (range: 29.7–94.2 h). The
resulting tumor dose showed a large variation (median:
7.2 Gy; range 0.2–30.6) (Table 3). A high correlation was
observed between the uptakes in PET and PRRT (Spear-
man’s rank test: P> 0.01). Figure 2 illustrates the post-
therapeutic scintigraphic whole body images acquired in
one patient. No acute toxicities were observed during
PRRT.
EBRT
A median dose of 53.0 Gy (range 41.8–60.0) was admi-
nistered in 26.7±4.3 fractions using IMRT (Table 3, Fig-
ure 1). The radiation dose delivered by PRRT showed
large variation; the EBRT target dose was significantly
reduced from the planned dose in four of the ten
patients because of concerns about anterior optic path-
way toxicity due to the summation of doses (Table 3,
Figure 1).
The other patients received EBRT as planned, irre-
spective of the PRRT, since the cumulative dose to
neighboring organs at risk was deemed not critical by
the responsible radiation oncologists. No unusual toxici-
ties were observed during radiotherapy (Figure 3).
Follow-up
As of November 2011 patients had a follow up of a me-
dian 13.4 months (range 4.3 months–17.0 months). All
patients were alive.
One patient (no. 9) reported a temporary worsening of
symptoms about 3–5 months after treatment, which
Figure 3 Side effects during EBRT according to CTCAE 4.0.
Figure 4 Model dose distribution (absorbed dose) comparing
peptide radionuclide therapy with 177Lu and 90Y respectively. A
homogeneous radionuclide dose distribution inside the tumor is
assumed.
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showed a good partial remission (>50%). Four patients
reported an improvement of their symptoms. On mor-
phological imaging, tumor size was stable in 8/10
patients; surprisingly, a complete remission was reported
in patient nr.4 on the MRI acquired three months after
EBRT. In the 7 patients who had a follow-up SSR-PET,
PET based volume estimates decreased to 81%± 21%
(range: 46%–107%; p = 0.029) of the original size. In all
of these 7 patients, the SUV values were higher after
therapy as compared to the baseline PET. SUVpeak
increased by a median of 34% (range: 8%–53%); the cor-
responding value for SUVmax was 37% (range: 15%–
46%).
No chronic effects>Grade 1 have been observed to
date after PRRT and EBRT; laboratory values remained
unchanged during follow-up.
Discussion
To the best of our knowledge, this is the first description
of combined external beam- PRRT for meningiomas.
The combination of these two therapeutic modalities
has only been described once in literature; Burdick et al.
combined EBRT with 90Y ibritumomab tiuxetan in
relapsed or refractory bulky follicular lymphoma [18].
They concluded that EBRT, used to pretreat bulky sites,
may improve clinical outcomes and potentially extend
survival when combined with radioimmunotherapy. Fur-
thermore, several preclinical mouse and rat model stud-
ies of heterotopic and orthotopic glioblastomas have
also found a positive synergistic effect of radionuclide
therapy and EBRT [19, 20]: by combining both, a stron-
ger reduction in tumor mass was measured than
achieved with either treatment modality alone.
Bartolomei et al. reported on single-modality-PRRT
using 90Y-DOTATOC as salvage monotherapy inpatients with advanced meningioma. Even though ther-
apy was well tolerated, the efficacy was limited, which
most likely can be attributed to the limited dose deliv-
ered to the tumor [15]. Recently, a successful treatment
of metastatic anaplastic meningioma with 177Lu-DOTA-
TATE has also been reported [14].
The small number of patients and short follow up pre-
clude a definitive answer regarding the efficacy of the
combination of EBRT and PRRT treatment. The overall
positive results (8 patients with morphologically stable
disease, one with partial and one with complete re-
sponse) after a median follow-up of 12.8 months are
promising. They compare favorably to the results
obtained by using the non-radioactive somatostatin
analogue octreotide [21, 22] and the study by Bartolomei
et al. [15]. Of course, direct comparison of this study
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and follow up. However, the short-term results in our
study appear to be superior even though the achieved
doses are lower than those published for PRRT in neu-
roendocrine tumors [23].
The current study furthermore has the limitation that
we, just like other hospitals, were forced to change from
the one somatostatin analogue (DOTATOC) to another
one (DOTATATE) due to a change in availability of the
GMP-grade precursor. Even though the difference be-
tween the two peptides is very small, it results in known
alterations of receptor binding and whole body kinetics.
Studies comparing the two peptides yield contradictory
results on which peptide is superior for clinical use [24,
25]. Nonetheless, as the different peptides do not differ
in their dosimetric methodology, this will not affect the
validity of the PRRT dosimetry.
In contrast to prior larger studies we opted to use
177Lu as the therapeutic radionuclide even though the
alternative, 90Y, has a six-fold higher energy depos-
ition per decay event. This is partly compensated for
by the higher activity that can be safely administered
and the longer physical half-life of 177Lu. The use of
177Lu has several advantages. Firstly, due to the co-
emitted gamma rays, dosimetry is easily feasible with
177Lu but challenging with the pure beta emitter 90Y,
especially in smaller structures. Secondly, renal tox-
icity is lower for 177Lu [26], which is particularly im-
portant for patients with a longer life expectancy.
Thirdly and most decisive, 177Lu has a much steeper
dose gradient curve than 90Y. Figure 4 shows a dose
distribution at the surface of a tumor with homoge-
neous 177Lu or 90Y activity uptake normalized to the
maximum absorbed dose inside the tumor. The calcu-
lations are based on point dose kernels published in
[27]. The relative dose decreases more rapidly with
177Lu than with 90Y. Tissue penetration outside the
tumor is negligible for 177Lu; at a distance of 0.3 mm
from the tumor surface, the dose delivered by radio-
nuclide therapy is less than 10% of the maximal
tumor dose. At least in theory, this should spare crit-
ical tissues immediately abutting the tumor (such as
cranial nerves and the chiasm). The isotope and activ-
ity to be used to treat a specific patient should there-
fore be selected based on individual parameters such
as tumor site, prognosis, radio peptide uptake, renal
function, and life expectancy.
In order to avoid severe adverse effects, we chose
to err on the side of caution and consequently the
target EBRT dose was reduced in four of the
patients with tumors very close to critical structures
(Figure 1). However, only long term observations
and further trials will allow better prediction of
whether such a measure is truly necessary as well aswhich patients will attain a significant dose benefit
from such a combined treatment.
Since radiotherapy as a stand-alone therapeutic
modality has a high success and disease control rate
even in large skull base meningiomas [28, 29], a
combined therapy might be most advantageous in
advanced cases with tumors in proximity to radio-
sensitive structures such as the optic nerve, in the
re-irradiation setting and for high-grade meningioma.
For a comparison of the absorbed doses of the two
treatment modalities (EBBRT and PRRT), several
authors suggest the application of the biologically
equivalent dose concept [30-32]. In the framework of
the present study, the quantities needed for the calcu-
lation of the tumor BED were unclear, so the
absorbed doses of both treatment modalities were
added. Future studies are needed to obtain the para-
meters for robust BED calculation.
An interesting finding is the increased uptake of
Ga-DOTATATE/DOTATOC in meningiomas after
the combined therapeutic approach. This was
observed in all 7 patients who were reimaged after
therapy (Table 2). In order to minimize the effects
of the usage of different PET scanners we assessed
both the SUVmax and the SUVpeak (the mean SUV in
a spherical VOI of 1 cm diameter). The increase was
observed for both parameters, so a significant effect
of the equipment used appears unlikely. Haug et al.
reported in a study on well differentiated neuroendo-
crine tumors that the tumor-to-spleen SUV ratio was
an independent predictor of a longer progression
free survival (PFS) after one cycle of PRRT. However,
the change of absolute SUVmax did not correlate
with PFS [33]. In our study, the tumor-to-spleen
-ratio was not calculated because the spleen was not
in the field of view. On the other hand, it is known
from preclinical studies that neuroendocrine tumors
recurring after PRRT have an increased SSR expres-
sion [33]. The observation of a SUVmax increase in
our patients is not necessarily an indicator of
increased receptor expression. Other possible expla-
nations might be an increased blood flow induced by
EBRT, the reduction in active tumor (cell) volume
after therapy as observed by PET delineation or by
reparative/reactive post-radiation changes. When cor-
rected for individual tumor shrinkage, the SUV
remains almost unchanged after therapy with a mean
deviation of 5% ± 24% (range: -31%–32%). Since no
patient progressed during follow-up, no conclusion
can be drawn from the present data whether the in-
crease in SUV correlates with prognosis as reported
in neuroendocrine tumors in the paper by Haug
et al. [33]. However, as a consequence from the ob-
servation of generally increasing SUV, PRRT could
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additionally as a second cycle.
Conclusions
Our experiences gained in this pilot phase indicate that
peptide receptor radionuclide therapy of meningiomas
may be safely used in combination with external beam
radiation therapy. This approach represents an attractive
strategy for the treatment of irresectable locally recur-
ring, progressive or symptomatic meningioma in order
to either increase the dose delivered to the tumor and /
or to reduce the dose for organs at risk. Further studies
are warranted on the basis of these results.
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